{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:16:26Z","timestamp":1790036186543,"version":"4.0.1"},"reference-count":32,"publisher":"American Association for Cancer Research (AACR)","issue":"18","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,9,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>We here describe a novel xenograft model of chronic lymphocytic leukemia (CLL) generated by infusion of human primary CLL cells into immunodeficient nonobese\/severe combined immunodeficient (NOD\/SCID) mice. Combined i.v. and i.p. injection of peripheral blood mononuclear cells (PBMC) from 39 patients with CLL resulted in highly reproducible splenic (37 of 39) and peritoneal (35 of 39) engraftment, which remained stable over a time span of 4 to 8 weeks. By comparison, recovery of leukemic cells from bone marrow (21 of 39) or peripheral blood (8 of 22) was substantially lower. The engraftment pattern of CLL PBMC 4 weeks posttransplant was correlated with clinical disease activity: infusion of PBMC from donors with Binet stage A, lymphocyte doubling time of &amp;gt;12 months, and normal lactate dehydrogenase (LDH) serum levels led to marked engraftment of T cells whereas comparably few tumor cells could be detected. In contrast, NOD\/SCID mice receiving PBMC from donors with advanced stage Binet C, lymphocyte doubling time of &amp;lt;12 months, and elevated LDH serum levels exhibited predominant engraftment of tumor cells and comparably low numbers of T cells. These results suggest that this model reflects the heterogeneity and important clinical characteristics of the disease, and thus may serve as a tool for preclinical drug testing and investigation of the pathophysiology of CLL. [Cancer Res 2007;67(18):8653\u201361]<\/jats:p>","DOI":"10.1158\/0008-5472.can-07-1198","type":"journal-article","created":{"date-parts":[[2007,9,17]],"date-time":"2007-09-17T13:53:12Z","timestamp":1190037192000},"page":"8653-8661","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["A Novel Nonobese Diabetic\/Severe Combined Immunodeficient Xenograft Model for Chronic Lymphocytic Leukemia Reflects Important Clinical Characteristics of the Disease"],"prefix":"10.1158","volume":"67","author":[{"given":"Jan","family":"Du\u0308rig","sequence":"first","affiliation":[{"name":"1Hematology, Departments of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Ebeling","sequence":"additional","affiliation":[{"name":"2Internal Medicine (Cancer Research), and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Grabellus","sequence":"additional","affiliation":[{"name":"3Pathology and Neuropathology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula R.","family":"Sorg","sequence":"additional","affiliation":[{"name":"2Internal Medicine (Cancer Research), and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Mo\u0308llmann","sequence":"additional","affiliation":[{"name":"2Internal Medicine (Cancer Research), and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Schu\u0308tt","sequence":"additional","affiliation":[{"name":"2Internal Medicine (Cancer Research), and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Go\u0308thert","sequence":"additional","affiliation":[{"name":"1Hematology, Departments of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludger","family":"Sellmann","sequence":"additional","affiliation":[{"name":"1Hematology, Departments of"},{"name":"4Institute of Cell Biology, University of Duisburg-Essen Medical School, Essen, Germany and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siegfried","family":"Seeber","sequence":"additional","affiliation":[{"name":"2Internal Medicine (Cancer Research), and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Flasshove","sequence":"additional","affiliation":[{"name":"2Internal Medicine (Cancer Research), and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Du\u0308hrsen","sequence":"additional","affiliation":[{"name":"1Hematology, Departments of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Moritz","sequence":"additional","affiliation":[{"name":"2Internal Medicine (Cancer Research), and"},{"name":"5Division of Experimental Hematology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2007,9,17]]},"reference":[{"key":"2022061623355698800_B1","unstructured":"Hummel JL, Lichty BD, Reis M, Dube I, Kamel-Reid S. Engraftment of human chronic lymphocytic leukemia cells in SCID mice: in vivo and in vitro studies. Leukemia\u20081996; 10: 1370\u20136."},{"key":"2022061623355698800_B2","doi-asserted-by":"crossref","unstructured":"Kobayashi R, Picchio G, Kirven M, et al. Transfer of human chronic lymphocytic leukemia to mice with severe combined immune deficiency. Leuk Res\u20081992; 16: 1013\u201323.","DOI":"10.1016\/0145-2126(92)90081-H"},{"key":"2022061623355698800_B3","doi-asserted-by":"crossref","unstructured":"Shimoni A, Marcus H, Canaan A, et al. A model for human B-chronic lymphocytic leukemia in human\/mouse radiation chimera: evidence for tumor-mediated suppression of antibody production in low-stage disease. Blood\u20081997; 89: 2210\u20138.","DOI":"10.1182\/blood.V89.6.2210"},{"key":"2022061623355698800_B4","unstructured":"Shimoni A, Marcus H, Dekel B, et al. Autologous T cells control B-chronic lymphocytic leukemia tumor progression in human-&gt;mouse radiation chimera. Cancer Res\u20081999; 59: 5968\u201374."},{"key":"2022061623355698800_B5","doi-asserted-by":"crossref","unstructured":"Schroers R, Griesinger F, Trumper L, et al. Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia. Leukemia\u20082005; 19: 750\u20138.","DOI":"10.1038\/sj.leu.2403707"},{"key":"2022061623355698800_B6","doi-asserted-by":"crossref","unstructured":"Hock H, Hamblen MJ, Rooke HM, et al. Gfi-1 restricts proliferation and preserves functional integrity of haematopoietic stem cells. Nature\u20082004; 431: 1002\u20137.","DOI":"10.1038\/nature02994"},{"key":"2022061623355698800_B7","doi-asserted-by":"crossref","unstructured":"Bonato M, Pittaluga S, Tierens A, et al. Lymph node histology in typical and atypical chronic lymphocytic leukemia. Am J Surg Pathol\u20081998; 22: 49\u201356.","DOI":"10.1097\/00000478-199801000-00006"},{"key":"2022061623355698800_B8","doi-asserted-by":"crossref","unstructured":"Deaglio S, Vaisitti T, Bergui L, et al. CD38 and CD100 lead a network of surface receptors relaying positive signals for B-CLL growth and survival. Blood\u20082005; 105: 3042\u201350.","DOI":"10.1182\/blood-2004-10-3873"},{"key":"2022061623355698800_B9","doi-asserted-by":"crossref","unstructured":"Granziero L, Circosta P, Scielzo C, et al. CD100\/Plexin-B1 interactions sustain proliferation and survival of normal and leukemic CD5+ B lymphocytes. Blood\u20082003; 101: 1962\u20139.","DOI":"10.1182\/blood-2002-05-1339"},{"key":"2022061623355698800_B10","doi-asserted-by":"crossref","unstructured":"Granziero L, Ghia P, Circosta P, et al. Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood\u20082001; 97: 2777\u201383.","DOI":"10.1182\/blood.V97.9.2777"},{"key":"2022061623355698800_B11","doi-asserted-by":"crossref","unstructured":"Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood\u20081999; 94: 1840\u20137.","DOI":"10.1182\/blood.V94.6.1840"},{"key":"2022061623355698800_B12","doi-asserted-by":"crossref","unstructured":"Deaglio S, Capobianco A, Bergui L, et al. CD38 is a signaling molecule in B-cell chronic lymphocytic leukemia cells. Blood\u20082003; 102: 2146\u201355.","DOI":"10.1182\/blood-2003-03-0989"},{"key":"2022061623355698800_B13","doi-asserted-by":"crossref","unstructured":"Durig J, Naschar M, Schmucker U, et al. CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia. Leukemia\u20082002; 16: 30\u20135.","DOI":"10.1038\/sj.leu.2402339"},{"key":"2022061623355698800_B14","doi-asserted-by":"crossref","unstructured":"Del Principe MI, Del Poeta G, Buccisano F, et al. Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. Blood\u20082006; 108: 853\u201361.","DOI":"10.1182\/blood-2005-12-4986"},{"key":"2022061623355698800_B15","doi-asserted-by":"crossref","unstructured":"Durig J, Nuckel H, Cremer M, et al. ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia. Leukemia\u20082003; 17: 2426\u201334.","DOI":"10.1038\/sj.leu.2403147"},{"key":"2022061623355698800_B16","doi-asserted-by":"crossref","unstructured":"Hamblin TJ. Predicting Progression-ZAP-70 in CLL. N Engl J Med\u20082004; 351: 856\u20137.","DOI":"10.1056\/NEJMp048184"},{"key":"2022061623355698800_B17","doi-asserted-by":"crossref","unstructured":"Orchard JA, Ibbotson RE, Davis Z, et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet\u20082004; 363: 105\u201311.","DOI":"10.1016\/S0140-6736(03)15260-9"},{"key":"2022061623355698800_B18","doi-asserted-by":"crossref","unstructured":"Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood\u20081999; 94: 1848\u201354.","DOI":"10.1182\/blood.V94.6.1848.418k05_1848_1854"},{"key":"2022061623355698800_B19","doi-asserted-by":"crossref","unstructured":"Shanafelt TD, Geyer SM, Kay NE. Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. Blood\u20082004; 103: 1202\u201310.","DOI":"10.1182\/blood-2003-07-2281"},{"key":"2022061623355698800_B20","doi-asserted-by":"crossref","unstructured":"Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med\u20082000; 343: 1910\u20136.","DOI":"10.1056\/NEJM200012283432602"},{"key":"2022061623355698800_B21","doi-asserted-by":"crossref","unstructured":"Burakova T, Marcus H, Canaan A, et al. Engrafted human T and B lymphocytes form mixed follicles in lymphoid organs of human\/mouse and human\/rat radiation chimera. Transplantation\u20081997; 63: 1166\u201371.","DOI":"10.1097\/00007890-199704270-00018"},{"key":"2022061623355698800_B22","doi-asserted-by":"crossref","unstructured":"Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer\u20081981; 48: 198\u2013206.","DOI":"10.1002\/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V"},{"key":"2022061623355698800_B23","doi-asserted-by":"crossref","unstructured":"Molica S, Alberti A. Prognostic value of the lymphocyte doubling time in chronic lymphocytic leukemia. Cancer\u20081987; 60: 2712\u20136.","DOI":"10.1002\/1097-0142(19871201)60:11<2712::AID-CNCR2820601122>3.0.CO;2-1"},{"key":"2022061623355698800_B24","doi-asserted-by":"crossref","unstructured":"Montserrat E, Sanchez-Bisono J, Vinolas N, Rozman C. Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance. Br J Haematol\u20081986; 62: 567\u201375.","DOI":"10.1111\/j.1365-2141.1986.tb02969.x"},{"key":"2022061623355698800_B25","unstructured":"Vinolas N, Reverter JC, Urbano-Ispizua A, Montserrat E, Rozman C. Lymphocyte doubling time in chronic lymphocytic leukemia: an update of its prognostic significance. Blood Cells\u20081987; 12: 457\u201370."},{"key":"2022061623355698800_B26","doi-asserted-by":"crossref","unstructured":"Rassenti LZ, Huynh L, Toy TL, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med\u20082004; 351: 893\u2013901.","DOI":"10.1056\/NEJMoa040857"},{"key":"2022061623355698800_B27","doi-asserted-by":"crossref","unstructured":"Decker T, Flohr T, Trautmann P, et al. Role of accessory cells in cytokine production by T cells in chronic B-cell lymphocytic leukemia. Blood\u20081995; 86: 1115\u201323.","DOI":"10.1182\/blood.V86.3.1115.bloodjournal8631115"},{"key":"2022061623355698800_B28","doi-asserted-by":"crossref","unstructured":"Mellstedt H, Choudhury A. T and B cells in B-chronic lymphocytic leukaemia: Faust, Mephistopheles and the pact with the Devil. Cancer Immunol Immunother\u20082006; 55: 210\u201320.","DOI":"10.1007\/s00262-005-0675-4"},{"key":"2022061623355698800_B29","unstructured":"Aguilar-Santelises M, Mellstedt H, Jondal M. Leukemic cells from progressive B-CLL respond strongly to growth stimulation in vitro. Leukemia\u20081994; 8: 1146\u201352."},{"key":"2022061623355698800_B30","doi-asserted-by":"crossref","unstructured":"Dadmarz R, Rabinowe SN, Cannistra SA, Andersen JW, Freedman AS, Nadler LM. Association between clonogenic cell growth and clinical risk group in B-cell chronic lymphocytic leukemia. Blood\u20081990; 76: 142\u20139.","DOI":"10.1182\/blood.V76.1.142.142"},{"key":"2022061623355698800_B31","doi-asserted-by":"crossref","unstructured":"Rossmann ED, Jeddi-Tehrani M, Osterborg A, Mellstedt H. T-cell signaling and costimulatory molecules in B-chronic lymphocytic leukemia (B-CLL): an increased abnormal expression by advancing stage. Leukemia\u20082003; 17: 2252\u20134.","DOI":"10.1038\/sj.leu.2403100"},{"key":"2022061623355698800_B32","doi-asserted-by":"crossref","unstructured":"Rossmann ED, Lewin N, Jeddi-Tehrani M, Osterborg A, Mellstedt H. Intracellular T cell cytokines in patients with B cell chronic lymphocytic leukaemia (B-CLL). Eur J Haematol\u20082002; 68: 299\u2013306.","DOI":"10.1034\/j.1600-0609.2002.01612.x"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/18\/8653\/2573626\/8653.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/18\/8653\/2573626\/8653.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:16:03Z","timestamp":1655424963000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/67\/18\/8653\/533515\/A-Novel-Nonobese-Diabetic-Severe-Combined"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9,15]]},"references-count":32,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2007,9,17]]},"published-print":{"date-parts":[[2007,9,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-07-1198","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.22368374.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22368380.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22368368.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22368383.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22368368","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22368377","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22368374","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22368371.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22368377.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22368383","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22368371","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22368380","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.6495938","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6495938.v1","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,9,15]]}}}